SOUTH SAN FRANCISCO, Calif. & LEXINGTON, Mass.–(BUSINESS WIRE)–Maze Therapeutics, a company focused on translating genetic insights into new medicines, and Alloy Therapeutics, a company developing platforms and services to enable drug discovery, today announced the formation of Broadwing Bio to develop targeted antibody therapies for the treatment of ophthalmic diseases.

Read more  here.